
The ketamine-assisted psychotherapy (KAP) market is projected to reach $3.4 billion, and with that growth comes regulatory scrutiny. DEA audits targeting controlled substance clinics have increased, and ketamine providers — particularly those offering at-home or telehealth-based treatment — face documentation requirements that go well beyond standard therapy notes.
If you are a clinician offering KAP, your documentation is your compliance. Here is what you need to know in 2026.
Standard psychotherapy notes follow familiar templates: presenting problem, interventions used, patient response, plan. KAP adds several layers of complexity:
Ketamine is a Schedule III controlled substance. Every prescription, every dose adjustment, and every refill must be documented with the same rigor applied to opioids or stimulants. Unlike SSRIs, you cannot simply write "continue current medication" — each prescribing decision requires clinical justification tied to documented assessment.
Dissociative state monitoring is required. During ketamine sessions, patients enter an altered state that demands real-time clinical observation. Your notes must capture vitals, level of consciousness, dissociative symptoms, and any adverse reactions at defined intervals throughout the session.
Informed consent is more detailed. Patients must understand that ketamine for depression, PTSD, and other psychiatric conditions is off-label. Your consent forms must address off-label use, potential side effects including dissociation and elevated blood pressure, the experimental nature of some treatment protocols, and alternatives to ketamine. A generic consent form will not pass regulatory review.
Every KAP provider should maintain the following for each patient:
As a Schedule III prescriber, you must maintain:
A DEA audit will examine whether your prescribing patterns are supported by documented clinical assessments. The most common audit finding is not over-prescribing — it is inadequate documentation of the clinical rationale for prescribing.
If you provide KAP via telehealth, documentation requirements vary by state. Key variables include:
Document your compliance with each applicable state requirement for every patient. For a general overview of ketamine's legal status, see Is Ketamine Legal?.
Manual documentation of all these requirements is time-consuming and error-prone. Several platforms have been developed specifically for ketamine providers:
The goal is not to spend more time on paperwork — it is to ensure that the paperwork you do produce is complete, defensible, and audit-ready.
At Isha Health, compliance documentation is built into every step of the treatment workflow. From initial screening through outcome tracking, our clinical team follows standardized protocols that satisfy both federal DEA requirements and state-specific telehealth regulations. This infrastructure is part of what allows us to offer safe, scalable at-home ketamine treatment.
If you are a clinician interested in how we approach compliance and clinical workflows, we welcome collaboration.
Are you a KAP-trained clinician? Collaborate with Isha Health or join our clinician directory.
88.8% of Isha Health patients with moderate-to-severe depression show measurable improvement
Based on 546 patients and 1,900+ validated assessments. See our clinical outcomes →
Stay informed on ketamine therapy
Research updates, clinical insights, and mental health resources — delivered to your inbox.